Based on a retrospective study, which provides a detailed comparison of demographic, clinicopathological, molecular, transcriptomic, and proteomic characteristics between HER2-positive (n = 1,286) and HER2-negative (n = 1,114) breast cancer patients (Figure 1). Here, ERBB2 is linked to breast carcinoma.